Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 150,456,256
  • Shares Outstanding, K 537,651
  • Annual Sales, $ 33,424 M
  • Annual Income, $ 4,090 M
  • EBIT $ 7,258 M
  • EBITDA $ 12,850 M
  • 60-Month Beta 0.59
  • Price/Sales 4.47
  • Price/Cash Flow 9.15
  • Price/Book 25.42

Options Overview Details

View History
  • Implied Volatility 33.43% ( -0.80%)
  • Historical Volatility 31.12%
  • IV Percentile 78%
  • IV Rank 40.51%
  • IV High 55.92% on 11/20/24
  • IV Low 18.11% on 05/21/24
  • Put/Call Vol Ratio 1.49
  • Today's Volume 5,006
  • Volume Avg (30-Day) 8,462
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 158,170
  • Open Int (30-Day) 180,088

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 4.15
  • Number of Estimates 12
  • High Estimate 4.45
  • Low Estimate 3.95
  • Prior Year 3.96
  • Growth Rate Est. (year over year) +4.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
267.40 +5.03%
on 04/09/25
315.00 -10.84%
on 03/31/25
-26.02 (-8.48%)
since 03/25/25
3-Month
267.40 +5.03%
on 04/09/25
335.88 -16.39%
on 03/10/25
+5.42 (+1.97%)
since 01/24/25
52-Week
253.30 +10.87%
on 12/19/24
346.85 -19.03%
on 07/25/24
+11.46 (+4.25%)
since 04/25/24

Most Recent Stories

More News
1 Value Stock to Research Further and 2 to Ignore

1 Value Stock to Research Further and 2 to Ignore

HLMN : 7.67 (+0.13%)
NXPI : 193.55 (-0.01%)
AMGN : 280.84 (+0.36%)
Analysts Think You Should Buy and Hold This 1 Dividend Stock ‘Forever’

Amgen stands out as a stable and attractive dividend stock, with a strong lineup of new medicines, a solid 3.45% forward yield, and a 201% dividend growth over the past decade.

$SPX : 5,525.21 (+0.74%)
AMGN : 280.84 (+0.36%)
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects. However, you don't necessarily have to sacrifice growth for safety.

VRTX : 493.84 (+0.28%)
LLY : 884.54 (+2.89%)
AMGN : 280.84 (+0.36%)
Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings?

AstraZeneca AZN will report its first-quarter 2025 earnings on April 29, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.68 billion and $1.10 per share, respectively....

AZN : 69.57 (+0.03%)
TEVA : 14.87 (+1.02%)
AMGN : 280.84 (+0.36%)
SNY : 52.32 (-2.28%)
Amgen's Quarterly Earnings Preview: What You Need to Know

Amgen is scheduled to report its first-quarter results next month, and analysts expect a single-digit earnings growth.

XLV : 138.05 (+0.48%)
$SPX : 5,525.21 (+0.74%)
AMGN : 280.84 (+0.36%)
Here's How You Should Play JNJ Stock After Q1 Earnings Beat

Earlier this week, J&J JNJ began the first-quarter earnings season for the drug and biotech sector with better-than-expected results.J&J’s first-quarter adjusted earnings were $2.77 per share, which...

JNJ : 154.58 (-0.23%)
KVUE : 23.01 (+1.14%)
TEVA : 14.87 (+1.02%)
AMGN : 280.84 (+0.36%)
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever

Equities are down this year because of Donald Trump's trade policies. The 47th U.S. president decided to impose steep tariffs on imported goods from most countries, although he has since significantly...

AZN : 69.57 (+0.03%)
NVS : 112.14 (+0.87%)
AMGN : 280.84 (+0.36%)
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

SRPT : 60.44 (-2.14%)
BMRN : 63.30 (+0.89%)
ABBV : 186.06 (+3.15%)
MRNA : 27.22 (-0.62%)
AMGN : 280.84 (+0.36%)
JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal

Johnson & Johnson’s JNJ first-quarter 2025 earnings came in at $2.77 per share, which beat the Zacks Consensus Estimate of $2.57. Earnings rose 2.2% from the year-ago period.Adjusted earnings exclude...

JNJ : 154.58 (-0.23%)
KVUE : 23.01 (+1.14%)
TEVA : 14.87 (+1.02%)
AMGN : 280.84 (+0.36%)
Sandoz Files Antitrust Lawsuit Against Amgen Over Inflammation Drug, Seeks Damages: Retail Sentiment Falters

Sandoz is seeking an injunction to prevent Amgen from using patent rights to block biosimilar competition and allow Sandoz to launch its Erelzi “as soon as possible.”

VOO : 506.11 (+0.74%)
VTI : 270.64 (+0.61%)
AMGN : 280.84 (+0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two...

See More

Key Turning Points

3rd Resistance Point 288.96
2nd Resistance Point 285.57
1st Resistance Point 283.21
Last Price 280.84
1st Support Level 277.46
2nd Support Level 274.07
3rd Support Level 271.71

See More

52-Week High 346.85
Fibonacci 61.8% 311.11
Fibonacci 50% 300.08
Fibonacci 38.2% 289.04
Last Price 280.84
52-Week Low 253.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar